US Regulatory Reads, October 2017: Horror Stories, Super Offices And Artificial Intelligence
Executive Summary
Our "terrifying tales" of US FDA inspections that went awry attracted, by far, the most readers last month. Also popular in October: Medtech Insight's reporting on the US agency's move to bring its device evaluation, compliance and surveillance activities all under one roof, and our deep-dive look at the promise and challenges of applying artificial intelligence to quality operations.
You may also be interested in...
FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks
The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.
Device Week, March 8, 2019 – Scott Gottlieb Resigns
On the latest Medtech Insight podcast, David Filmore and Ferdous Al-Faruque discuss the unexpected news that Scott Gottlieb is leaving US FDA next month. What has been his legacy for medtech, and who will replace him?
Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.